A PHASE 1 STUDY OF TJ033721 IN SUBJECTS WITH ADVANCED OR METASTATIC SOLID TUMORS.

Brief description of study

You can participate in this study if you are diagnosed with advanced solid tumors. The purpose of this study is to test the safety of a study drug called TJ033721. The study will test different dose levels to find out what effects, both good and/or bad, the study treatment has on you and your solid tumor. The study drug, TJ033721, is investigational and has been tested in animals, but not yet in people. This means it has not been approved for commercial use by the United States Food and Drug Administration (FDA). This study tests up to 8 different doses of the study drug to see which dose is safe in people. The dose you receive will depend on when you start the study. The study drug’s effects will be measured by testing samples of your blood, scanning your tumor area, and in some cases taking a biopsy of your tumor. The study staff will also watch for physical changes after you are given the study drug.


Clinical Study Identifier: s22-00431
ClinicalTrials.gov Identifier: NCT04900818
Principal Investigator: Kristen Spencer.
Other Investigators: Nila Theresa De La Rosa, Joshua K Sabari, Samantha VanMaanen, Eneil De La Pena, Jeffrey S. Weber, Jessica Wang, Elaine Shum, Salman Rafi Punekar, Scot Niglio, Keriann M Scavone, Vamsidhar Velcheti, Kathleen M Madden, Caitlin Elizabeth Ryan, David R. Wise, Nina Beri, Janice Mehnert, Douglas K Marks.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.